Interestingly, a recent study showed that a combination of bosutinib and the thymidylate synthase inhibitor capecitabine, an oral fluoropyrimidine that delivers 5-FU to the tumor, was well tolerated and showed therapeutic promise in a variety of cancers. The gene discussed is TYMS; the disease is cancer.